Manava Plus is a biotech and medtech startup developing neurotechnology for spinal cord injury. The company is working on a biohybrid implant intended to restore communication across damaged spinal pathways and recover lost motor and sensory function. It positions the technology around paralysis treatment, with the broader aim of turning severe spinal injury into a more manageable and potentially reversible condition.

While technical details remain limited, the platform appears to combine implantable neuromodulation with regenerative or biologically integrated elements. The approach is designed to reconnect disrupted signalling between the brain and body, while potentially supporting longer-term functional recovery. This places the company at the intersection of neurostimulation, spinal repair, and bioelectronic medicine.

Manava Plus is focused on applications in paralysis and spinal cord rehabilitation. Its technology is aimed at restoring movement, sensation, and other functions affected by spinal injury. The company reflects a broader effort in neurotechnology to pair stimulation-based approaches with biological repair strategies for severe neurological damage.